
CLAIMS

What is claimed is:


1. Use of aficamten



(aficamten),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in a patient in need thereof, wherein the patient has been diagnosed with oHCM within 12 months before aficamten, or a pharmaceutically acceptable salt thereof, is to be administered.

2. Use of aficamten




(aficamten),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in a patient in need thereof, wherein the patient is treatment naïve for oHCM.

3. The use of claim 1, wherein aficamten, or a pharmaceutically acceptable salt thereof, is to be administered as a monotherapy for oHCM.

4. Use of aficamten




(aficamten),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in a patient in need thereof, wherein aficamten, or the pharmaceutically acceptable salt thereof, is to be administered as a monotherapy for oHCM, and wherein the patient has chronic oHCM and has previously received standard of care medical therapy for oHCM and has discontinued said therapy before aficamten, or a pharmaceutically acceptable salt thereof, is to be administered.

5. The use of claim 4, wherein the standard of care medical therapy comprises treatment with one or more therapeutics selected from a beta-blocker, a calcium channel blocker, and disopyramide.

6. The use of claim 1, wherein the patient has an LVEF ≥ 60% before aficamten, or a pharmaceutically acceptable salt thereof, is to be administered.

7. Use of aficamten




(aficamten),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in a patient in need thereof, wherein the patient is receiving one or more background therapies for oHCM and at least one background therapy is to be reduced and/or stopped.

8. The use of claim 7, wherein at least one background therapy is to be reduced.

9. Use of aficamten



(aficamten),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in a patient in need thereof, wherein:


(1) aficamten, or a pharmaceutically acceptable salt thereof, is to be administered in combination with a first dose of a standard-of-care therapeutic for oHCM, for a first time period; and

(2) aficamten, or a pharmaceutically acceptable salt thereof, is to be administered in combination with a second dose of the standard-of-care therapeutic for oHCM, for a second time period,

wherein the second dose of the standard-of-care therapeutic for oHCM is lower than the first dose of the standard-of-care therapeutic.

10. The use of claim 9, wherein the second dose of the standard-of-care therapeutic for oHCM is 50% of the first dose of the standard-of-care therapeutic, or lower.

11. Use of aficamten



(aficamten),


or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in a patient in need thereof, wherein:

(1) aficamten, or a pharmaceutically acceptable salt thereof, is to be administered in combination with a standard-of-care therapeutic for oHCM, for a first time period; and

(2) aficamten, or a pharmaceutically acceptable salt thereof, is to be administered as a monotherapy, for a second time period.

12. The use of claim 9, wherein the patient in need thereof has been receiving the standard-of-care therapeutic for oHCM before aficamten is to be administered.

13. Use of aficamten



(aficamten),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in a patient in need thereof, wherein:

(1) a background therapy comprising at least one standard-of-care therapeutic selected from the group consisting of beta blockers, non-dihydropyridine calcium channel blockers, and disopyramide, is to be administered;


(2) aficamten, or a pharmaceutically acceptable salt thereof, is to be administered in combination with the background therapy, for a first time period; and

(3) aficamten, or a pharmaceutically acceptable salt thereof, is to be administered in combination with a second dose of the standard-of-care therapeutic for oHCM, for a second time period,

wherein the second dose of the standard-of-care therapeutic for oHCM is lower than the first dose of the standard-of-care therapeutic.

14. The use of claim 13, wherein the second dose of the standard-of-care therapeutic for oHCM is 50% of the first dose of the standard-of-care therapeutic, or lower.

15. Use of aficamten



(aficamten),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in a patient in need thereof, wherein:

(1) a background therapy comprising at least one standard-of-care therapeutic selected from the group consisting of beta blockers, non-dihydropyridine calcium channel blockers, and disopyramide, is to be administered;


(2) aficamten, or a pharmaceutically acceptable salt thereof, is to be administered in combination with the background therapy, for a first time period; and

(3) aficamten, or a pharmaceutically acceptable salt thereof, is to be administered as a monotherapy, for a second time period.

16. The use of claim 9, wherein the first time period is at least 12 weeks.

17. The use of claim 9, wherein a therapeutically effective amount of aficamten, or a pharmaceutically acceptable salt thereof, is selected by titrating a daily dose of aficamten, or a pharmaceutically acceptable salt thereof, to be administered to the patient.

18. Use of aficamten



(aficamten), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving myocardial mechanics or global longitudinal strain (GLS) in a patient in need thereof, wherein the patient has obstructive hypertrophic cardiomyopathy (oHCM).

19. The use of claim 18, wherein a therapeutically effective amount of aficamten, or a pharmaceutically acceptable salt thereof, is selected by titrating a daily dose of aficamten, or a pharmaceutically acceptable salt thereof, to be administered to the patient.

20. The use of claim 1, wherein the aficamten or pharmaceutically acceptable salt thereof comprises one or more of polymorphic Form I, Form II, Form III, Form IV, Form V, and Form VI of aficamten.